US Patent

US11389447 — Aqueous suspensions of TMC278

Method of Use · Assigned to Janssen Sciences Ireland ULC · Expires 2027-06-30 · 1y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions of TMC278 for intramuscular or subcutaneous injection to treat and prevent HIV infection.

USPTO Abstract

This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.

Drugs covered by this patent

Vocabria (CABOTEGRAVIR) · GSK

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3405`	—	Vocabria
`U-3405`	—	Vocabria

Patent Metadata

Patent number: US11389447
Jurisdiction: US
Classification: Method of Use
Expires: 2027-06-30
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Sciences Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.